NCT05809908 - Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study | Biotech Hunter

Enrollment

535

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2029

Conditions

Alzheimer Disease

Interventions

DRUG

Tricaprilin

"Each dose of IMP will be administered orally 30 minutes after completing a full meal.~There is 1 g of tricaprilin per 2 ml of AC-OLE-01-VA.~Participants will titrate from 5 g twice a day to 20 g twice a day, up to 40 g total daily dose of tricaprilin; 80 ml total daily dose of AC-OLE-01-VA, over the course of 2-4 weeks."

DRUG

Placebo

"Each dose of IMP will be administered orally 30 minutes after completing a full meal.~Participants will titrate from 5 g twice a day to 20 g twice a day, up to 40 g total daily dose of placebo; 80 ml total daily dose of placebo, over the course of 2-4 weeks."